Get the latest news alerts: at Twitter.

Local Tech Wire

RALEIGH, N.C. – (Nasdaq: BDSI) hopes to submit a new drug application to the Food and Drug Administration by the end of 2011 for its proposed treatment that would limit nausea and vomiting linked to cancer therapy.

BDSI reported Monday that the company had a “positive outcome” from a meeting with the FDA about BEMA Graniestron. BEMA refers to the company’s technology through which drugs can be delivered through the lining of the mouth.

Based on the meeting, BDSI said further clinical efficacy studies might be be required.

“We believe that the ability to administer granisetron using the BEMA drug delivery technology may offer patients a means to prevent cancer therapy induced nausea and vomiting without the need to swallow oral tablets or receive an intravenous injection,” said Andrew Finn, BDSI’s executive vice president of product development.

BDSI already sells a powerful drug that targets breakthrough cancer pain. It utilizes BEMA, or bioerodible mucoadhesive, technology.